PTEN and breast carcinoma: Although loss of the PTEN tumor suppressor, or the presence of PI3KCA gain-of-function mutations can lead to constitutive activation of PI3K signaling in breast cancer [33,34], neither was found to be relevant in our models of resistance (data not shown).